AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12721399 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (Zn)
Number of subjects: 109
Study 12721399 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper (Cu)
Number of subjects: 109
Study 10469709 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mmol/l taurine
Number of subjects: 0
Study 10469709 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mmol/l glutamine
Number of subjects: 0
Study 10469709 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mmol/l glutamine and 5 mmol/l taurine
Number of subjects: 0
Study 10469709 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention specified)
Number of subjects: 0
Study 8694034 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 31
Study 8694034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 1913008 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose oil 6 g/day
Number of subjects: 40
Study 1913008 — intervention group
Group type: COMPARATOR
Intervention: Olive oil 6 g/day (placebo)
Number of subjects: 40
Study 7038918 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 15
Study 7038918 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 15
Study 7038918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31904304 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious Illness Care Program (SICG)
Number of subjects: 159
Study 31904304 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 159
Study 30778558 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low SQB (n = 213)
Number of subjects: 2309
Study 30778558 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SQB (n = 1035)
Number of subjects: 2309
Study 30778558 — intervention group
Group type: EXPERIMENTAL
Intervention: High SQB (n = 588)
Number of subjects: 2309
Study 30778558 — intervention group
Group type: EXPERIMENTAL
Intervention: Very high SQB (n = 473)
Number of subjects: 2309
Study 30778558 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall SQB levels
Number of subjects: 2309
Study 29066597 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR)
Number of subjects: 9
Study 29066597 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 9
Study 26234526 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg resveratrol supplementation
Number of subjects: 50
Study 26234526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 23618891 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive consultation with occupational physician (41% of group 1)
Number of subjects: 369
Study 23618891 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mental health intervention (16% of group 2)
Number of subjects: 369
Study 23618891 — intervention group
Group type: EXPERIMENTAL
Intervention: WHS mental module
Number of subjects: 369
Study 23618891 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall WHS process
Number of subjects: 369
Study 21212381 — intervention group
Group type: EXPERIMENTAL
Intervention: Story-focused brief with state-level data
Number of subjects: 291
Study 21212381 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-focused brief with state-level data
Number of subjects: 291
Study 21212381 — intervention group
Group type: COMPARATOR
Intervention: Data-focused brief with local-level data
Number of subjects: 291
Study 21212381 — intervention group
Group type: COMPARATOR
Intervention: Story-focused brief with local-level data
Number of subjects: 291
Study 18661066 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential supracrestal fibrotomy
Number of subjects: 21
Study 18661066 — intervention group
Group type: COMPARATOR
Intervention: Non-surgery
Number of subjects: 21
Study 16528713 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 90
Study 16528713 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 90
Study 12783053 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV, N = 18)
Number of subjects: 67
Study 12783053 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RES, N = 18)
Number of subjects: 67
Study 12783053 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (PL, N = 19)
Number of subjects: 67
Study 12783053 — intervention group
Group type: COMPARATOR
Intervention: Control group (CO, N = 12)
Number of subjects: 67
Study 10711541 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 41
Study 10711541 — intervention group
Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 41
Study 9109102 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (15, 50, and 150 mg)
Number of subjects: 0
Study 9109102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1591163 — intervention group
Group type: EXPERIMENTAL
Intervention: NHS nursing homes
Number of subjects: 0
Study 1591163 — intervention group
Group type: COMPARATOR
Intervention: Conventional long stay hospital wards
Number of subjects: 0
Study 3978996 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (225 gm)
Number of subjects: 10
Study 30947915 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation (RSD)
Number of subjects: 977
Study 30622617 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial acupuncture
Number of subjects: 40
Study 30622617 — intervention group
Group type: COMPARATOR
Intervention: Traditional acupuncture
Number of subjects: 40
Study 28025355 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour chronic pain educational session
Number of subjects: 346
Study 28025355 — intervention group
Group type: COMPARATOR
Intervention: treatment as usual (normal wait-list)
Number of subjects: 346
Study 26148947 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training program integrated into primary health center visits, delivered in group format at 5 routine visits from age 3 to 18 months, including short films, discussions, demonstrations, and distribution of message cards and play materials.
Number of subjects: 501
Study 26148947 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 501
Study 26148947 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training program.
Number of subjects: 501
Study 24220547 — intervention group
Group type: EXPERIMENTAL
Intervention: BEST MOOD (family based intervention)
Number of subjects: 160
Study 24220547 — intervention group
Group type: COMPARATOR
Intervention: PAST (active control condition)
Number of subjects: 160
Study 21348810 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral levosimendan
Number of subjects: 29
Study 21348810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 18316716 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with a single spatial frequency stimulus
Number of subjects: 0
Study 18316716 — intervention group
Group type: COMPARATOR
Intervention: Normal observers
Number of subjects: 0
Study 16536958 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived patient demand for antibiotics
Number of subjects: 1448
Study 16536958 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal lung auscultation with perceived patient demand
Number of subjects: 1448
Study 16536958 — intervention group
Group type: EXPERIMENTAL
Intervention: One abnormal auscultatory finding with perceived patient demand
Number of subjects: 1448
Study 14617264 — intervention group
Group type: EXPERIMENTAL
Intervention: VO2max in CHF patients
Number of subjects: 20
Study 14617264 — intervention group
Group type: COMPARATOR
Intervention: VO2max in control subjects
Number of subjects: 20
Study 14617264 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of VO2max with mean SDH activity
Number of subjects: 20
Study 14617264 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum oxygen uptake rate per unit muscle fibre length
Number of subjects: 20
Study 11712030 — intervention group
Group type: EXPERIMENTAL
Intervention: PDGF gel
Number of subjects: 7
Study 11712030 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic ointment
Number of subjects: 7
Study 9696196 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical diagnosis for cervicitis
Number of subjects: 1233
Study 9696196 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical diagnosis for trichomoniasis
Number of subjects: 1233
Study 9696196 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory tests for gonorrhoea, chlamydia infection, and trichomoniasis
Number of subjects: 1233
Study 8063984 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive, individualized cognitive therapy (10 sessions over 8 weeks)
Number of subjects: 20
Study 8063984 — intervention group
Group type: COMPARATOR
Intervention: Daily gastrointestinal (GI) symptom monitoring (8 weeks)
Number of subjects: 20
Study 3194864 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg terbutaline (five puffs)
Number of subjects: 11
Study 3194864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31049671 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session music intervention (SMI)
Number of subjects: 100
Study 31049671 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 27940291 — intervention group
Group type: EXPERIMENTAL
Intervention: Retromuscular mesh repair
Number of subjects: 180
Study 27940291 — intervention group
Group type: COMPARATOR
Intervention: Onlay technique
Number of subjects: 180
Study 25323734 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine (2 g per day orally, divided into two doses, taken 6 h after chemotherapeutic agents)
Number of subjects: 40
Study 23297332 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital mammography plus tomosynthesis
Number of subjects: 12631
Study 23297332 — intervention group
Group type: COMPARATOR
Intervention: Digital mammography alone
Number of subjects: 12631
Study 21330902 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (cART)
Number of subjects: 2141
Study 21330902 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotoxic ART (nART)
Number of subjects: 2141
Study 19815817 — intervention group
Group type: EXPERIMENTAL
Intervention: ITX5061
Number of subjects: 0
Study 16452592 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled heparin (50,000 IU, twice daily for 2 weeks)
Number of subjects: 18
Study 16452592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 14977665 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture anchor fixation
Number of subjects: 9
Study 14977665 — intervention group
Group type: COMPARATOR
Intervention: Bone tunnel fixation
Number of subjects: 9
Study 11977347 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy using abdominal wall lift
Number of subjects: 0
Study 11977347 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy using pneumoperitoneum
Number of subjects: 0
Study 11977347 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 0
Study 9447290 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutation at codon 918 (ATG to ACG) found in peripheral blood and MTC tissue from the MEN 2B patient.
Number of subjects: 7
Study 9447290 — intervention group
Group type: COMPARATOR
Intervention: PCR-SSCP analysis of exons 10 and 11, and restriction enzyme digestion methods for exons 13 and 16.
Number of subjects: 7
Study 7523548 — intervention group
Group type: EXPERIMENTAL
Intervention: CYFRA 21-1 serum levels
Number of subjects: 239
Study 7523548 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA serum levels
Number of subjects: 239
Study 7523548 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 125 serum levels
Number of subjects: 239
Study 7523548 — intervention group
Group type: EXPERIMENTAL
Intervention: SCC serum levels
Number of subjects: 239
Study 7523548 — intervention group
Group type: EXPERIMENTAL
Intervention: NSE serum levels
Number of subjects: 239
Study 31327563 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of supervised primaquine (1·0 mg/kg per day)
Number of subjects: 2336
Study 31327563 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 days of supervised primaquine (0·5 mg/kg per day)
Number of subjects: 2336
Study 31327563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2336
Study 31327563 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of primaquine
Number of subjects: 2336
Study 31327563 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 days of primaquine
Number of subjects: 2336
Study 29216446 — intervention group
Group type: EXPERIMENTAL
Intervention: Low volume per session with high frequency (LV-HF)
Number of subjects: 18
Study 29216446 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume per session with low frequency (HV-LF)
Number of subjects: 18
Study 27002161 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathy group (brief empathetic statements included)
Number of subjects: 437
Study 27002161 — intervention group
Group type: COMPARATOR
Intervention: Non-empathy group (no empathetic statements)
Number of subjects: 437
Study 27002161 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathy group
Number of subjects: 437
Study 24821096 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-session intervention utilizing psychoeducation and interoceptive exposure techniques to target anxiety sensitivity (AS)
Number of subjects: 108
Study 24821096 — intervention group
Group type: COMPARATOR
Intervention: Health information control intervention
Number of subjects: 108
Study 22924607 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cholecalciferol (4000-100,000 IU per week)
Number of subjects: 0
Study 22924607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20453562 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching method using Standardized Patients (SPs)
Number of subjects: 62
Study 20453562 — intervention group
Group type: COMPARATOR
Intervention: Traditional practice education (Control)
Number of subjects: 62
Study 18716497 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedles (various designs)
Number of subjects: 10
Study 18716497 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedle length
Number of subjects: 10
Study 18716497 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of microneedles
Number of subjects: 10
Study 18716497 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedle tip angle, thickness, and width
Number of subjects: 10
Study 18716497 — intervention group
Group type: COMPARATOR
Intervention: 26-gauge hypodermic needle
Number of subjects: 10
Study 16042223 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNβ‐1a‐Avonex 30 μg intramuscularly once weekly for six years
Number of subjects: 382
Study 12629096 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily)
Number of subjects: 15
Study 12629096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10337083 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal Group
Number of subjects: 360
Study 10337083 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Group
Number of subjects: 360
Study 10337083 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face Group
Number of subjects: 360
Study 9112170 — intervention group
Group type: EXPERIMENTAL
Intervention: Trephination with scleral auto-implant plug soaked with Mitomycin-C (0.2 mg/ml for 5 minutes)
Number of subjects: 67
Study 9112170 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with Mitomycin-C
Number of subjects: 67
Study 1748532 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis and subsequent pulse cyclophosphamide
Number of subjects: 0
Study 1748532 — intervention group
Group type: COMPARATOR
Intervention: Pulse cyclophosphamide alone
Number of subjects: 0
Study 7095718 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein isocaloric diet for seven days
Number of subjects: 24
Study 7095718 — intervention group
Group type: COMPARATOR
Intervention: Low protein isocaloric diet for seven days
Number of subjects: 24
Study 7095718 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet
Number of subjects: 24
Study 7095718 — intervention group
Group type: COMPARATOR
Intervention: Low protein diet
Number of subjects: 24
Study 28838290 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Behavioral Activation Treatment (MBAT) for 8 weeks
Number of subjects: 80
Study 28838290 — intervention group
Group type: COMPARATOR
Intervention: Regular treatment (Control)
Number of subjects: 80
Study 29986673 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic sequencing and report including monogenic disease variants, recessive carrier variants, and pharmacogenomic variants.
Number of subjects: 0
Study 29986673 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving genomic sequencing).
Number of subjects: 0
Study 26711160 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol 20 mg three times a day and lofexidine 0.6 mg three times a day
Number of subjects: 156
Study 26711160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 24853059 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural treatment protocol (CBSPp) with treatment as usual (TAU), 24 sessions
Number of subjects: 49
Study 24853059 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 49
Study 24853059 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural treatment protocol (CBSPp)
Number of subjects: 49
Study 23042121 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical leadership position with both social and financial resources
Number of subjects: 0
Study 23042121 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical leadership position with financial resources but no social resources
Number of subjects: 0
Study 23042121 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical leadership position with social resources but no financial resources
Number of subjects: 0
Study 23042121 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's evaluations of leadership positions
Number of subjects: 0
Study 23042121 — intervention group
Group type: EXPERIMENTAL
Intervention: Men's evaluations of leadership positions
Number of subjects: 0
Study 20931422 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic-containing yogurt (Bifidobacterium DN-173 010-1010 cfu/g) 125 ml before breakfast for 14 days
Number of subjects: 76
Study 20931422 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (pantoprazole 40 mg b.i.d., amoxicillin 1000 mg b.i.d., clarithromycin 500 mg b.i.d. for 14 days)
Number of subjects: 76
Study 18809049 — intervention group
Group type: EXPERIMENTAL
Intervention: MarginProbe device
Number of subjects: 300
Study 18809049 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 300
Study 16190915 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg naratriptan
Number of subjects: 275
Study 16190915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study 12352805 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitors (indinavir, saquinavir, ritonavir, nelfinavir)
Number of subjects: 68
Study 9935109 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg of IM progesterone given 12 hours before oocyte retrieval
Number of subjects: 314
Study 9935109 — intervention group
Group type: COMPARATOR
Intervention: 25 mg of IM progesterone given on the day of oocyte retrieval
Number of subjects: 314
Study 7594142 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive equations for BMR: BMR = 13.88 x weight (kg) + 4.16 x height (cm) - 3.43 x age (years) - 112.40 x sex (men = 0; women = 1) + 54.34
Number of subjects: 223
Study 7594142 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect calorimetry measurement of BMR
Number of subjects: 223
Study 1979946 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 26
Study 6160639 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg per day for one week
Number of subjects: 21
Study 6160639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 31151855 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety monitoring brochure/infographic
Number of subjects: 150
Study 31151855 — intervention group
Group type: COMPARATOR
Intervention: Unrelated brochure
Number of subjects: 150
Study 30567527 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX-4 chemotherapy (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, 5-fluorouracil bolus 400 mg/m2 + infusion 600 mg/m2 for 2 days every 3 weeks)
Number of subjects: 29
Study 30567527 — intervention group
Group type: COMPARATOR
Intervention: Topotecan (1.5 mg/m2 every three weeks)
Number of subjects: 29
Study 26016510 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold Weight (GW)
Number of subjects: 18
Study 26016510 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous Temporalis Fascia (TF)
Number of subjects: 18
Study 26016510 — intervention group
Group type: COMPARATOR
Intervention: Contralateral eyelid (control)
Number of subjects: 18
Study 24803301 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-led intervention (fathers taught their families about farm safety)
Number of subjects: 151
Study 24803301 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff-led intervention (staff members who were peer farmers taught families)
Number of subjects: 151
Study 24803301 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 151
Study 24803301 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-led and staff-led interventions
Number of subjects: 151
Study 21643644 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradetrusor botulinum toxin-A (BTX-A)
Number of subjects: 32
Study 20450723 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed hyperuricemic intervention
Number of subjects: 531
Study 18619971 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine consisting of recombinant VacA, CagA, and NAP with aluminium hydroxide as an adjuvant
Number of subjects: 57
Study 18619971 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine consisting of recombinant VacA, CagA, and NAP
Number of subjects: 57
Study 18619971 — intervention group
Group type: COMPARATOR
Intervention: Alum controls
Number of subjects: 57